Evaluation of drug-drug interactions associated with metamizole in clinical practice
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2026.2630755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Tom G Jacobs und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands. Hauptthemen laut MEDLINE: Dipyrone, Anti-Inflammatory Agents, Non-Steroidal, Cytochrome P-450 Enzyme Inducers. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Metamizole, a non-steroidal anti-inflammatory drug and moderate inducer of cytochrome P450 enzymes (CYP3A4, CYP2B6, CYP2C19), has gained increased use in clinical practice. This retrospective study evaluates the number of drug-drug interactions (DDIs) associated with metamizole when prescribed for ≥24 h. RESEARCH DESIGN AND METHODS: Data were collected from the electronic healthcare records of adult patients prescribed metamizole at Tergooi Medical Center between June 2017 and May 2024. Relevant DDIs with metamizole were identified using the Metamizole DDI Manager developed by Global DDI Solutions. Only clinically relevant, i.e. orange (action may be needed) and red (contra-indicated), DDIs that occurred during or within seven after discontinuation of metamizole treatment in a hospital setting were considered. RESULTS: A total of 37,110 unique patients received at least one metamizole prescription of which 2.6% (n = 968) were treated for ≥24 h. Of these, 98.6% (n = 954) were prescribed at least one interacting medication. In total, 3680 DDIs were identified, corresponding to an average of 3.8 DDIs per metamizole prescription. Of the 98 interacting medications identified, 95% were classified as orange, and 5% as red. CONCLUSIONS: In conclusion, metamizole is associated with a many DDIs in clinical practice. This highlights the need for careful monitoring when prescribed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
- Department of Pharmacy, Pharmacology & Toxicology, Research Institute for Medical Innovations (RIMI), Radboud UMC, Nijmegen, The Netherlands.
- Department of Anaesthesiology, Tergooi Medical Center, Hilversum, The Netherlands.
- Global DDI Solutions, Utrecht, The Netherlands.
Zitieren
APA
Jacobs, T. G., van den Eijnde, S. E. J. D., Nijboer, L., Kylstra, A., Nicia, S. B., Burger, D. M., van der Linden, P. D., & van Nuland, M. (2026). Evaluation of drug-drug interactions associated with metamizole in clinical practice. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2630755
Vancouver
Jacobs TG, van den Eijnde SEJD, Nijboer L, Kylstra A, Nicia SB, Burger DM, et al. Evaluation of drug-drug interactions associated with metamizole in clinical practice. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2630755
BibTeX
@article{Jacobs2026,
author = {Jacobs, Tom G and van den Eijnde, Sharon E J D and Nijboer, Laura and Kylstra, Anke and Nicia, Steven B and Burger, David M and van der Linden, Paul D and van Nuland, Merel},
title = {Evaluation of drug-drug interactions associated with metamizole in clinical practice},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2630755}
}
EUVIMED